Skip to main content
padlock icon - secure page this page is secure

Update on Hsp90 Inhibitors in Clinical Trial

Buy Article:

$68.00 + tax (Refund Policy)

Twenty-five years ago the first small molecule inhibitors of Hsp90 were identified. In the intervening years there has been dramatic progress in basic scientific understanding of the Hsp90 chaperone machinery and in the role of Hsp90 in malignancy. The first-in-class Hsp90 inhibitor 17-AAG entered into Phase I clinical trials in 1999. There are now 13 Hsp90 inhibitors in clinical trial, representing multiple drug classes, and hundreds of patients have been treated in adult oncology and pediatric oncology trials. This review will provide an overview of the clinical trial results thus far. In addition, pivotal issues in further development of Hsp90 inhibitors as anticancer drugs will be discussed.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Hsp90 inhibitors; clinical trial; targeted therapy

Document Type: Research Article

Affiliations: Medical Oncology Branch, NCI, Bldg 10, Rm 12N230, NIH, 10 Center Drive, Bethesda, MD 20892, USA.

Publication date: November 1, 2009

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more